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ess: loy.i.britto@gsk.coSummary In response to the Montreal Protocol, a salmeterol (SereventTM)
metered dose inhaler (MDI) has been developed containing the non-chlorofluor-
ocarbon propellant, hydrofluoroalkane 134a (HFA), to replace the marketed
SereventTM chlorofluorocarbon (CFC) propellant MDI.
This paper details the pharmaceutical assessment of salmeterol HFA MDI and confirms
that this product meets the current Committee for Proprietary Medicinal Products
regulatory requirements, and is comparable to the CFC MDI in product performance.
Criteria investigated included fine particle mass (FPM), dose delivery and uniformity,
priming requirements and simulated-use-testing. Dose delivery was unaffected by
changing product orientation during storage. The mean dose delivered per actuation
ranged from 21.3 to 22.4mg, and all individual doses were within the725% defined limits
of the target ex-actuator dose of 21mg. The FPM results, defined as the mass of particles
between 1.1 and 4.7mm in diameter (the sum of the mass deposited on stages 3–5 of the
Andersen Cascade Impactor), were similar for the HFA and CFC products. The mean FPM
values of the two HFA clinical batches were 8.7 and 10.1mg, covering the values obtained
during the development, and the one of the CFC clinical batch was 10.0mg. Comparability
in aerosol characteristics was also demonstrated when the salmeterol HFA inhaler was
tested using a large volume spacer (VolumaticTM).
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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m (I.L. Britto).Introduction
The environmental reasons for replacement of
chlorofluorocarbon (CFC) propellants, as defined in
the Montreal protocol, are well known.1 Selection
of the replacement propellant, hydrofluoroalkane
134a (HFA) has necessitated reformulation ofed.
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Pharmaceutical development of salmeterol HFA MDI S21metered dose inhalers (MDIs) due to the differences
in solubility of drugs and excipients in HFA.2,3 To
facilitate the transition from CFC to HFA formula-
tion for the patient and prescriber, the new MDI
formulations are required to be similar in appear-
ance and use, clinically non-inferior with the same
recommended dosage and pharmaceutically com-
parable with a similar product performance.4
In order to meet these requirements, an HFA
formulation containing only drug and propellant has
been developed to deliver 60 doses of salmeterol,
which corresponds to a label claim of 120 actua-
tions each of 25 mg of salmeterol. The HFA inhaler
comprises of a modified valve using a novel
elastomer and a coated can. In comparison, the
CFC formulation comprises drug, propellant and
surfactant with a conventional valve and a non-
coated can.
The HFA inhaler was tested in compliance with
the requirements defined by the Committee for
Proprietary Medicinal Products (CPMP).5 The key
product performance criteria of the accuracy and
consistency of dosing of the HFA inhaler and the
FPM of the delivered drug were determined. These
data were compared with that generated from the
CFC inhaler, in conjunction with tests for dosing
through life in simulated use tests. In addition, the
particle size distribution (PSD) of drug delivered
from the HFA inhaler was evaluated in the presence
and absence of a large volume spacer.
This paper presents details of the pharmaceutical
testing of salmeterol HFA metered dose inhaler
(25 mg per actuation) and provides a fully evaluated
assessment of dosing characteristics to provide
assurance of consistent quality in the HFA product
performance in comparison with that previously
described for the CFC inhaler.Methods
Definition of dose ex-actuator and actuator
deposition
The content of salmeterol per actuation can
be expressed either as the amount delivered from
the valve (ex-valve, or the metered dose), or
the amount delivered from the actuator (ex-
actuator or the delivered dose). The average
amount of salmeterol deposited on the actuator
after each actuation has been determined as 4 mg.
Therefore, although the label claim metered dose
of the salmeterol inhaler is 25 mg, the nominal
delivered dose of salmeterol per actuation is
21 mg.Definition of priming requirements prior to
first use
As with all metered-dose inhalers, it is necessary
for the patient to discharge a number of priming
actuations to waste before using an inhaler for the
first time.6 These priming actuations are required
to reliably establish the delivery of the label claim
dose prior to patient usage. To determine the
number of priming actuations required before first
use of the inhaler, six single actuations were
collected and analysed for salmeterol content per
actuation separately from three individual un-
primed inhalers.
Content uniformity
A content uniformity test for a metered-dose
inhaler gives assurance that the content of drug per
actuation is consistent throughout the label claim
number of actuations and that this is consistent
between inhalers in a batch. This test involves
assaying the first dose and last label claim dose
from ten inhalers, where a dose constitutes the
mean of two consecutive actuations, namely
actuations 1 and 2 and actuations 119 and 120.
Twenty doses, i.e. twenty data points, are gener-
ated when performing the test. This method
complies with the CPMP Guidelines for Metered
Dose Inhalation Products5 that recommend, in
addition to the intra-can content uniformity assess-
ment, that the uniformity of the dose between an
appropriate number of canisters be evaluated.
Testing 10 canisters at beginning and end of use
assesses both inter-can as well as intra-can varia-
bility.
Simulated use testing
In addition to the content uniformity tests used
to evaluate the dosing behaviour of the proposed
product through use, the dosing characteristics
were also studied over the label claim number of
actuations (i.e.120) using the recommended pa-
tient use regime. The method used to study
salmeterol metered dose inhaler in this simu-
lated-use test is summarised below.
Two actuations (corresponding to a dose) were
discharged twice a day with an approximately 8-h
interval between the morning and afternoon
actuations and then an approximately 16-h interval
between the afternoon actuations and the actua-
tions the following morning. The inhalers were
stored horizontally at ambient temperature be-
tween each pair of actuations delivered. At defined
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I.D. Peyron et al.S22points throughout the discharge of the label claim
number of actuations, the dose delivered was
assayed. Each of the content per actuation results
is a mean of a composite sample of two actuations.Dose delivery performance through to
exhaustion of inhaler contents
Salmeterol inhaler is designed to deliver 120
actuations. To ensure that the inhaler will deliver
the label claim number of actuations over the
period of the proposed shelf life, an overfill of
suspension is included in the formulation. In order
to give an assurance of acceptable dosing through
the label claim content of the inhalers, studies
have been performed to evaluate the content per
actuation and the weight per actuation through use
and to exhaustion.
The dosing characteristics of the product have
been assessed through use and from the last label
claim number of actuations to the final exhaustion
point of the inhaler. The aim of the experiment was
to demonstrate that acceptable dosing character-
istics are maintained up to the final exhaustion
point for each of the inhalers under test.
Three inhalers were assayed at beginning of use
(BOU, mean of actuations 1 and 2) and at end of use
(EOU, mean of actuations 119 and 120). The
actuations between the label claim number of
actuations and final exhaustion were then dis-
charged and the content of salmeterol per actua-
tion was determined intermittently. In the
approach to final exhaustion, the content of
salmeterol per actuation and the weight of suspen-
sion delivered per actuation were determined for
successive individual actuations.Dose delivery performance as a function of
storage orientation
Studies have been conducted to investigate the
content reproducibility of salmeterol inhaler when
used regularly according to the recommended
dosing regimen. The reproducibility test involvesTable 1 Effective cut-off diameter (ECD) for the stage
Stage 0 1 2 3
ECD (mm) 9.0 5.8 4.7 3
ECD ¼ 50% cut-off diameter at a flow of 28.3 l per minute me
yAndersen Cascade Impactor refers to the Andersen One ACFM
with the small volume metal inlet ‘‘throat’’ as described in Eurothe discharge of two actuations (corresponding to a
dose) twice a day with an approximately 8-h
interval between morning and afternoon actuations
and then an approximately 16-h interval between
the afternoon actuations and the actuations the
following morning. This regimen continues until 14
actuations have been discharged; the test there-
fore being conducted over 4 days. Each dose
delivered (mean of two consecutive actuations)
was collected and assayed. Each of the content per
actuation results is a mean of a composite sample
of 2 actuations. Following discharge of the actua-
tions the inhalers were stored in one of three
orientations: valve horizontal; valve down and
valve up. These studies have been carried out on
three inhalers stored in each of the three valve
orientations.
Particle size distribution testing using an
Andersen Cascade Impactor
All of the aerodynamic particle size distribution
data for salmeterol inhaler have been generated
using the Andersen Cascade Impactor7 fitted with a
small volume metal inlet ‘throat’ as described in
the European Pharmacopoeia (Ph.Eur.).8
The Andersen Cascade Impactor is a multi-stage
impactor system through which the aerosol cloud
discharged from the inhaler under test is drawn.
Drug particles are deposited on the various stages
depending on their aerodynamic particle size. By
analysing the amounts of drug deposited on the
various stages of the cascade impactor, it is possible
to generate aerodynamic particle size distribution
information for the product under examination.
The effective cut-off diameters for each stage of
the impactor system when operated at a flow rate
of 28.3 l/min are given in Table 1.
As recommended by the Ph.Eur. (8) the number
of discharges has been minimised as close to the
minimum patient dose as possible taking analytical
sensitivity into consideration. Hence, the particle
size distribution analysis on salmeterol inhaler is
performed using 4 actuations, i.e. two times the
minimum patient dose of two actuations.s of the Andersen Cascade Impactor.y
4 5 6 7
.3 2.1 1.1 0.7 0.4
asured at the entrance of the metal ‘‘throat’’.
Ambient (non-viable) Cascade Impactor used in conjunction
pean Pharmacopoeia.8
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Pharmaceutical development of salmeterol HFA MDI S23Comparisons between CFC and HFA inhalers
The use of HFA propellant has required the
modification of components of the valve to im-
prove the quality of the product from a perfor-
mance standpoint. The elastomers used in the
CFC inhalers are not compatible with HFA and
changes in the rubber formulation have resulted
in a cleaner compound with a significantly lower
extraction profile and improved product per-
formance. Also, the internal surfaces of the
aluminium cans have been treated to improve drug
delivery from the inhaler over the life of the
product.
The primary aim of the development work was
to obtain comparable in vitro performance for the
aerodynamic particle size distribution between
salmeterol HFA inhaler and salmeterol CFC in-
haler. In order to facilitate this comparison the
particle size distributions of salmeterol HFA inha-
lers and salmeterol CFC inhalers were measured
using the Andersen Cascade Impactor. The two
clinical batches of salmeterol HFA inhaler were
compared with the clinical batch of the CFC
inhaler. Those HFA batches have been manufac-
tured with the purpose to cover the range of fine
particle mass obtained during the development.
Three individual inhalers were tested for each
batch.
A statistical analysis comparing the salmeterol
HFA MDI to the salmeterol CFC MDI regarding fine
particle mass has been performed on a greater
number of FPM mean values (17 batches for each of
HFA and CFC) from clinical, development and
stability batches representative of the HFA product
that will be marketed, and on current marketed
CFC product. The following statistical methods
have been used:
Normal probability plots: They are useful as they
allow a visual comparison of the data. The data are
arranged in order of magnitude and plotted on the
vertical y-axis. The horizontal x-axis represents
appropriate percentage points from a normal
distribution. If the data are from a normal
distribution, then the plot will fall approximately
along a straight line. For a normal distribution, the
mean will be the y value corresponding to zero on
the x-axis, and the standard deviation can be
estimated from the slope of the line.
F-test: This compares the variances in each
data set.
t-test: This compares the means of each
data set and estimates the probability that
the observed difference could occur by chance,
given that the true population means are the
same.Comparison of in vitro performance of
salmeterol HFA inhaler fitted with
conventional and modified valves
The Andersen Cascade Impactor was used to
measure the particle size distribution of salmeterol
HFA metered dose inhalers when the same batch of
drug suspension is filled into cans fitted with the
modified valve and the conventional valve. These
batches were also subject to accelerated stability
testing, and the particle size distribution was
measured after storage at 40 1C/75% relative
humidity (RH) for 6 months.
Comparison of particle size distribution data
with and without a VolumaticTM spacer
Cascade impaction data have been generated to
show the performance, in terms of the fine particle
mass and particle size distribution, for salmeterol
HFA inhaler used with and without the VolumaticTM
spacer. Three inhalers were tested without any
spacer and three inhalers were tested with the
VolumaticTM spacer from the same batch of
product.Results
Definition of priming requirements prior to
first use
The data obtained are presented in Fig. 1. Limits
have been placed on the graph purely for refer-
ence, based on 725% of the overall mean content
of salmeterol per actuation derived from the
content uniformity release testing of the same
batch.
The data obtained indicate that the content of
salmeterol per actuation is close to target after the
first or priming actuation (indicated by the label P
in Fig. 1), with good agreement between the three
inhalers tested. The salmeterol content per actua-
tion after the priming actuation, P, (actuation 1 to
actuation 5) is very consistent and remains close to
the target. These data support the recommenda-
tion that, prior to first use, the inhaler should be
primed by discharging one actuation to waste.
Content uniformity
Data are presented in Table 2 for the mean
content per actuation for 10 inhalers from each of
three batches. These data show that the content
uniformity of the salmeterol HFA inhalers is well
ARTICLE IN PRESS
Table 2 Content uniformity results for salmeterol HFA inhalers (10 inhalers from three batches).
Content uniformity results (in micrograms, ex-actuator label claim dose 21 mg)
Inhaler number Inhaler batch
Batch 1 Batch 2 Batch 3
BOU EOU BOU EOU BOU EOU
1 21.81 23.15 22.74 22.75 20.44 20.95
2 22.11 20.96 21.09 20.98 20.96 21.49
3 20.56 22.38 21.02 22.08 20.03 21.23
4 21.63 22.63 21.02 21.61 20.49 21.85
5 21.65 24.10 21.25 21.97 20.48 22.04
6 21.79 22.69 19.92 21.75 20.07 23.73
7 22.32 23.79 20.51 23.30 21.92 22.13
8 22.46 21.72 20.76 22.74 20.37 20.83
9 22.42 24.35 19.86 22.06 20.81 22.43
10 22.08 23.63 20.66 21.82 20.31 23.11
Overall mean of 20 results 22.4 21.5 21.3
715% Of label claim ex-actuator dose 17.8–24.2
725% Of overall mean 16.8–28.0 16.1–26.9 16.0–26.6
Number of values outside 725% of mean 0 0 0
BOU ¼ beginning of use, EOU ¼ end of use.
As defined by CPMP guidelines for content uniformity.5
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Figure 1 Number of priming actuations required before first use of salmeterol inhaler.
I.D. Peyron et al.S24within acceptable limits. The overall mean content
per dose value is within 715% of the target ex-
actuator dose of 21 mg. All of the individual values
are within 725% of the overall mean, which
complies with CPMP guidelines.5 The inter-can,
intra-can and inter-batch content uniformity are
evaluated in this test and shown to be consistent.Simulated use testing
Results for the salmeterol content per
actuation for 10 inhalers are shown in Fig. 2. The
limits indicated on the graph demonstrate that
there are no values outside 725% of the mean
value.
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Figure 2 Salmeterol content per actuation through life in a simulated use test. (single batch, 10 inhalers tested).
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Figure 3 Comparison of the salmeterol content per actuation with the weight per actuation through use and to
exhaustion.
Pharmaceutical development of salmeterol HFA MDI S25The data shows consistent dosing through to the
label claim number of actuations. The data provide
confidence that the product delivers the required
salmeterol content per actuation through use when
actuations are delivered in a regimen consistent
with the recommended patient use.Dose delivery performance through to
exhaustion of inhaler contents
The data obtained are presented in Fig. 3 for one
inhaler and are representative of the three inhalerstested from the same batch. The data show the
content of salmeterol per actuation and the weight
per actuation for the actuations after the end of
use (EOU) actuation number of 120. Limits have
been placed on the graph, purely for reference,
based on 725% of the overall mean content per
actuation derived from the content uniformity
release testing of the batch. The results show that
up to the exhaustion phase, the content per
actuation for individual actuations lies within
725% of the overall mean content. At final inhaler
exhaustion, the salmeterol content per actuation
decreases steeply in line with the weight per
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I.D. Peyron et al.S26actuation over the last 3–4 actuations thereby
providing a very clear indication to the patient that
exhaustion of the contents has been reached.
The content of salmeterol per actuation data
generated between label claim number of actua-
tions and final exhaustion provides confidence that
the proposed product will deliver an acceptable
dose beyond the label claim number of actuations
and up to the point of exhaustion.Dose delivery performance as a function of
storage orientation
The results from this test are shown in Fig. 4 for
the mean values of 3 inhalers tested in each storage
orientation from the same batch, and are the mean
of two actuations at each time point. They show
good consistency between each pair of actuations,
irrespective of the storage orientation. The indivi-
dual values range from 20.2 to 23.4 mg per actua-
tion and are within725% of the target ex-actuator
dose of 21 mg.Particle size distribution testing using an
Andersen Cascade Impactor
The particle size distribution of salmeterol HFA
inhalers was measured using the Andersen Cascade
Impactor. Three inhalers were tested from each of
two clinical trial batches. The mean fine particle
mass (FPM) results, defined as the mass of particles
between 1.1 and 4.7 mm in diameter (the mass of
particles on stages 3, 4 and 5 of the Andersen0.0
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Figure 4 Dose delivery performance as a function of stora
simulated use test regime.Cascade Impactor) are 10.1 and 8.7 mg for the two
batches.Comparison of performance with
conventional and modified valves
Figure 5 shows the particle size distribution
measured by cascade impactor of salmeterol HFA
inhalers fitted with conventional and modified
valves. This figure clearly demonstrates significant
difference in FPM stability performance between
the two valves. After storage for 6 months at 40 1C/
75% RH, there is a dramatic change in particle size
distribution profile with the conventional valve.
The total fine particle mass with the conventional
valve drops significantly to 5.8 mg, compared to
9.8 mg for the modified valve, following storage for
6 months at 40 1C/75% RH.Comparison of performance with the CFC
and HFA products
Results obtained for the two clinical batches of
salmeterol HFA inhaler (with a treated can and a
modified valve) and the clinical batch of salmeterol
CFC inhaler are presented in Fig. 6. The corre-
sponding fine particle mass mean values are 8.7 mg
(individual values between 8.1 and 9.5 mg) and
10.1 mg (individual values between 9.5 and 10.6 mg)
for the HFA inhaler batches which cover the range
of FPM obtained during the development, and
10.0 mg (individual values between 9.4 and
10.3 mg) for the CFC inhaler batch. 2 pm Day 3 am Day 3 pm Day 4 am
Valve up
Valve Horizontal
Valve Down
+/- 25% of mean
ge orientation for 3 inhalers from the same batch, in a
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Figure 5 Comparison of cascade impaction profiles of salmeterol HFA inhalers fitted with a modified valve and a
conventional valve.
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Figure 6 Comparison of cascade impaction profiles of salmeterol HFA inhaler and salmeterol CFC inhaler.
Pharmaceutical development of salmeterol HFA MDI S27The statistical analysis comparing the salmeterol
HFA MDI to the salmeterol CFC MDI has been done
on the FPM mean values listed in Table 3.
The normal probability plots (Fig. 7) fall approxi-
mately along straight lines for both data sets
demonstrating a normal distribution of both CFC
and HFA.Summary statisticsCFC HFAMean 10.02941 9.401961
SD 1.322187 0.539093
N 17 17
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I.D. Peyron et al.S28where SD is the standard deviation, N is the number
of FPM mean values.Table 3 Fine particle mass means of the salme-
terol HFA MDI and the salmeterol CFC MDI including
clinical, development and stability batches.
Fine particle mass (mg)
Salmeterol CFC inhaler Salmeterol HFA inhaler
10.2 10.1
11.0 10.2
10.6 9.6
11.7 10.2
10.4 9.2
11.0 10.1
9.6 8.7
9.6 8.8
12.0 9.1
8.4 9.1
7.2 9.0
7.4 9.7
10.3 9.8
10.6 9.1
10.9 9.4
9.8 8.8
10.0 8.9
Normal Probability Plots for FPM
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Figure 7 Comparison of normal probability plotComparison of variances: C
tan
s oF-ratio ¼ 6.0153,
P ¼ 0:0009;
the F-ratio is the ratio of the variances.The F-test indicates that the HFA data is certainly
no more variable than the CFC data, and in fact
shows less variation (P-value ¼ 0.0009).
Comparison of means assuming unequal variances:difference ¼ 0.63,
t-value ¼ 1.8118,
df ¼ 21.18,
P ¼ 0.0842,where df is the number of degrees of freedom
associated with the standard error.
The t-test, under the assumption of unequal
variances, does not provide sufficient evidence
that the population means should not be considered
equal (P-value ¼ 0.0842). The observed 0.6 mg
difference between the CFC and HFA fine particle
mass means is not statistically significant. Then
salmeterol HFA inhaler and salmeterol CFC inhaler
are similar in terms of fine particle mass. As a
consequence, Fig. 6 shows that the particle size
distributions are similar.oded by Product
 CFC
 HFA0.5 1.0 1.5 2.0
0.75 0.85 0.95
dardized)
f HFA and CFC fine particle mass means.
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Pharmaceutical development of salmeterol HFA MDI S29This is confirmed by the results of the clinical
studies demonstrating that salmeterol HFA MDI is as
effective as salmeterol CFC MDI.10
Comparison of particle size distribution data
with and without a VolumaticTM spacer
The mean particle size distribution profiles
obtained from 3 individual inhalers for use with
and without the VolumaticTM spacer are given in
Fig. 8. The particle size distribution profiles show
that there is no significant change to the shape of
the deposition profile on stages 3, 4 and 5 when the
salmeterol HFA inhaler is used with and without the
VolumaticTM spacer.Discussion
The data from these studies show that it has been
possible to formulate a salmeterol HFA pMDI with a
similar in vitro pharmaceutical performance to the
CFC pMDI.
The content uniformity results show excellent
consistency, with all individual measured values
complying with CPMP guidelines by being within the
limits of 725% of the labelled claim ex-actuator
dose. To establish patient confidence in product
performance of the salmeterol HFA inhaler, the
product is tested under conditions simulating
patient use, employing real-time dosing regimens0.0
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4.0
6.0
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Figure 8 Comparison of the particle size distribution pro
VolumaticTM spacer.and different valve orientations for the canister
storage. Storage orientation of the valve in the
inhaler, and priming requirements, are important
tests to establish pharmaceutical properties of drug
suspension formulations, which may cream or
sediment on standing. However, in these experi-
ments, the dose consistency has been demonstrably
maintained through the life of the inhaler in a
simulated patient-use regimen, irrespective of
storage orientation. The CPMP guideline limits of
725% of the dose content5 shown in Figs. 2 and 4
provide a clear indication of the consistency of
dosing from the salmeterol HFA inhaler.
The particle size distribution of the active
ingredient from the HFA pMDI and CFC pMDI was
determined using the Andersen Cascade Impactor.
The size distribution of fine drug particles in the
discharged aerosol correlates to the in vivo
penetration of particles into the airways.9 The
HFA pMDI particle size distributions are similar to
those from the corresponding CFC pMDI, so this
suggests that the total lung deposition character-
istics of those devices are also similar. The fine
particle mass results shown in Fig. 5 for the
modified valve and Fig. 6 for the salmeterol HFA
inhaler are comparable with the CFC product,
showing that the formulation modifications to the
valve and the coating of the internal can surface
facilitate the good dosing performance.
The addition of a spacer device had no significant
effect on the shape of the deposition profile for
stages 3, 4 and 5 for the salmeterol HFA pMDI,Stage 3 Stage 4 Stage 5 Stage 6 Stage 7 Filter
eterol HFA Inhaler with Volumatic Spacer
eterol HFA Inhaler without  Spacer
files for salmeterol HFA inhaler with and without the
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I.D. Peyron et al.S30although there was a slight increase in fine particle
mass. The slight increase in fine particle mass is
likely to be due to the deceleration of the aerosol
through the spacer and increased droplet evapora-
tion within the spacer. However, the differences are
unlikely to be of clinical significance given the inter-
patient variability seen with inhaled drug delivery.
The results of this study demonstrated that the
replacement of CFC propellants with non-ozone
depleting HFA in pMDIs has now become feasible for
salmeterol, without affecting the pharmaceutical
characteristics and performance of the device.Acknowledgements
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